New medicine that spur weight loss and treat diabetes have been having the public—and also the pharmaceutical market—by storm. The most recent entrant, Zepbound, not too long ago joined Ozempic, Wegovy, Victoza and others in a expanding course of prescription drugs named GLP-one receptor agonists.Some even clearly show promising signs of managi